Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
InMed Pharmaceuticals ( (INM) ) has provided an update.
InMed Pharmaceuticals announced promising preclinical results for its drug candidate INM-901, which significantly reduces neuroinflammation in Alzheimer’s disease models. The study highlights INM-901’s potential as a therapeutic candidate, demonstrating a reduction in key pro-inflammatory markers independent of amyloid beta or tau pathology, which could position it as a distinctive treatment option for Alzheimer’s and other neurodegenerative diseases.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
InMed Pharmaceuticals shows significant financial challenges with persistent losses and negative cash flows, which heavily weigh down its score. The stock’s technical indicators reflect short-term positive momentum, offering some optimism amid volatility. The valuation remains constrained by ongoing losses and lack of profitability metrics, typical for the biotechnology sector.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company’s pipeline includes three separate programs aimed at addressing diseases with high unmet medical needs.
Average Trading Volume: 1,351,018
Technical Sentiment Signal: Sell
Current Market Cap: $3.01M
Learn more about INM stock on TipRanks’ Stock Analysis page.